Company intelligence / Profile preview

Neuronyx, Inc.

Malvern, Pennsylvania, United Statesneuronyx.site ↗

Ownership: Private
Development stage: Phase 1

Overview

Neuronyx developed stem cell-based therapies using adult bone marrow-derived cells to repair damaged heart tissue after myocardial infarction and later targeted surgical wound healing. Despite promising early results and significant venture funding ($55M+), the company discontinued its programs after rebranding as Garnet BioTherapeutics due to inability to sustain operations.[5][8]

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Cellular therapiesStem cell therapy (specifically adult bone marrow-derived stem cells)[3][5]
Industry: Biotech

Drug pipeline

1 asset

NX-CP105

Partnerships

No major pharmaceutical or biotech partnerships publicly documented.

Beyond the preview

Go deeper on Neuronyx, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronyx, Inc..

Explore the full profile